Abbey Jenkins
Chief Executive Officer at GAMIDA CELL LTD.
Net worth: 10 467 $ as of 2024-04-29
Abbey Jenkins active positions
Companies | Position | Start | End |
---|---|---|---|
GAMIDA CELL LTD. | Director/Board Member | 2022-09-16 | - |
Chief Executive Officer | 2022-09-16 | - | |
President | 2022-09-16 | - | |
AQUESTIVE THERAPEUTICS, INC. | Director/Board Member | 2024-03-31 | - |
Independent Dir/Board Member | 2024-03-31 | - | |
XORTX THERAPEUTICS INC. | Director/Board Member | 2024-04-07 | - |
Interstitial Cystitis Association of America, Inc. | Director/Board Member | - | - |
Career history of Abbey Jenkins
Former positions of Abbey Jenkins
Companies | Position | Start | End |
---|---|---|---|
Lyndra Therapeutics, Inc.
Lyndra Therapeutics, Inc. Packaged SoftwareTechnology Services Lyndra Therapeutics, Inc. develops software technology for oral drug formulations. It offers pharmacology, therapeutic impact, reduced pill burden, and reduced care giver burden. The company was founded by Amy W. Schulman, Carlo Giovanni Traverso, Andrew Bellinger, and Robert S. Langer Jr. in 2015 and is headquartered in Watertown, MA. | Corporate Officer/Principal | 2021-02-28 | 2022-07-31 |
RELYPSA INC | Corporate Officer/Principal | 2014-02-28 | 2016-04-30 |
ALLERGAN PLC | Corporate Officer/Principal | 2011-08-31 | 2013-08-31 |
Medimmune, Inc. | Sales & Marketing | 2011-02-28 | 2011-08-31 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | 2016-05-24 | - |
Training of Abbey Jenkins
Indiana University | Undergraduate Degree |
The Johns Hopkins University | Graduate Degree |
Statistics
International
United States | 9 |
Canada | 3 |
Ireland | 2 |
Operational
Corporate Officer/Principal | 4 |
Director/Board Member | 4 |
Sales & Marketing | 1 |
Sectoral
Health Technology | 8 |
Consumer Services | 3 |
Technology Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
GAMIDA CELL LTD. | Health Technology |
AQUESTIVE THERAPEUTICS, INC. | Health Technology |
XORTX THERAPEUTICS INC. | Health Technology |
Private companies | 6 |
---|---|
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Relypsa, Inc.
Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Allergan Ltd. (Ireland)
Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
Medimmune, Inc. | Health Technology |
Interstitial Cystitis Association of America, Inc. | |
Lyndra Therapeutics, Inc.
Lyndra Therapeutics, Inc. Packaged SoftwareTechnology Services Lyndra Therapeutics, Inc. develops software technology for oral drug formulations. It offers pharmacology, therapeutic impact, reduced pill burden, and reduced care giver burden. The company was founded by Amy W. Schulman, Carlo Giovanni Traverso, Andrew Bellinger, and Robert S. Langer Jr. in 2015 and is headquartered in Watertown, MA. | Technology Services |
- Stock Market
- Insiders
- Abbey Jenkins
- Experience